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The role of lipid metabolism in relation to psoriasis has been
the subject of numerous investigations since the work of GrUtz
and BUrger (1) who found extreme hyper-cholesterolemia asso-
ciated with the disease. They expressed the belief that a dis-
turbance of fat metabolism was the cause of the skin lesions and
obtained beneficial effects with low fat diets. Gate, Chanial,
Vallet and Humbert (2) found an increase in serum cholesterol
in 70 per cent of their patients who showed clinical evidence of
psoriasis. Pulay (3) observed derangement of lipid metabolism
in patients with psoriasis, but did not consider this as the cause
of the disease. He was of the opinion, however, that an altered
fat metabolism may play an important role in the pathogenesis of
psoriasis. The cholesterol tolerance test as used by Grütz and
Burger (1) was employed in ten psoriatic patients by Rosen,
Rosenfeld and Krasnow (4). On the basis of this test the authors
could not assume that a disturbance of fat metabolism was
present, although they showed that hypo-cholesterolemia existed
in patients with psoriasis. Hering (5) after studying this ques-
tion denied that there was any relationship between fat metab-
olism and psoriasis. More recently Madden (6) concluded that
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hypercholesterolemia does not exist in psoriasis and that the
cholesterol tolerance test was of no value. He found that low
fat diets were of definite value in 68 per cent of patients with
psoriasis, but believed that the favorable effect of the diet could
be explained on the basis of a general realignment of metabolism
and tissue function rather than on the basis of restoration of
disturbed fat metabolism.
LIPOCAIC
The recent report by Dragstedt, Prohaska and Harms (7)
showed that the pancreas manufactures, in addition to insulin,
another hormone which seems to be concerned in some way with
the metabolism of fat. It had been discovered by Fisher (8)
that completely depancreatized dogs adequately treated with
insulin usually failed to survive more than two or three months.
At autopsy the most obvious change was extensive fatty infiltra-
tion of the liver. The addition of raw pancrease to the diet was
found by Macleod and his associates (12), at about the same time,
to prevent the development of liver change and to permit survival
for long periods of time, Dragstedt, Prohaska and Harms (7)
reported that 1 to 1.5 grams of a neutral alcoholic extract of
pancreas, rendered free of fat by extraction with ether, was
effective in preventing the deposition of fat in the liver of depan-
creatized dogs. They concluded that the action of this pan-
creatic extract was due to the presence of an internal secretion, a
hormone to which they gave the name "lipocaic." There is very
little known concerning the function of this new hormone.
Together with insulin it seems to be essential for life and in its
absence a specific defect is produced. As was noted before, this
is manifested by extreme infiltration of the liver with fat and very
pronounced decrease in concentration of fat in the blood (9).
The administration of lipocaic produces marked elevation in the
blood lipids and at the same time causes disappearance of the
large amount of fat in the liver. There is some evidence which
suggests that under the influence of lipocaic this fat is in part
converted into glucose. Sufficient evidence, however, has not
yet been obtained as to whether this new hormone has to do with
oxidation of fat or is mainly concerned with fat transportation (9).
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Many theories have been advanced as to the cause of psoriasis,
but at the present time the cause still remains unknown and the
treatment unsatisfactory as regards cure, although relief can
usually be obtained. Our determination to investigate the effect
of lipocaic in the treatment of psoriasis was based largely on our
success in considerably reducing the blood lipids in patients with
xanthoma. This work will be published at a future date.
Lipocaic possibly can establish the same metabolic state in a
patient as a low-fat diet, but has the advantages that a patient
can eat a regular diet and does not need hospitalization for dietary
regulation. Madden (6) believed hospitalization to be the most
important factor in the effect of diet on psoriasis. Schamberg
(10) also observed the benefit of hospitalization when he did his
work on the effect of a low protein diet in psoriasis.
EXPERIMENTAL
Six cases form the basis of this paper. Although the series is
small due to the difficulty of obtaining sufficient lipocaic, which
at present is available oniy for experimental use, it seemed worth-
while to make a preliminary report of our results to date. Of the
six cases presented three were children and three were adults.
The sex was equally divided. The selection of patients was
based merely upon their willingness to cooperate and the available
supply of lipocaic. The patients were instructed to stop all
previous therapeutic measures. No dietary or other restrictions
were imposed. The sole treatment consisted of the oral adminis-
tration of lipocaic capsules three times daily; no local applications
were used. The number of capsules (7- grains each) ingested
per day varied from 8 to 14. The amount of lipocaic contained
in each capsule was equivalent to 25 grams of raw pancreas. The
patients returned without breakfast at intervals of two weeks,
when the clinical progress was noted and blood was drawn for
determination of total lipids. The determinations of the total
blood serum lipids were made by a modification of the Wilson
method (11), as follows:
Three cubic centimeters of blood serum were mixed with about 60 cubic centi-
meters of "alcohol-ether" (3 parts of dehydrated alcohol and 1 part ether).
The mixture was shaken thoroughly and allowed to stand for 24 hours. Several
222 THE JOURNAL OF INVESTIGATIVE DERMATOLOGY
glass beads were added to prevent bumping and the extraction mixture was
refluxed in a water bath for twenty minutes. The extract was filtered while
still hot through a fat free filter paper into a 125 cubic centimeter Erlenmeyer
flask. The protein precipitate was washed several times with small portions
of the mixture of alcohol and ether. The filtrate was evaporated to dryness in
air at room temperature. The total lipid was then determined by the gravi-
metric method. The residue was suspended in 4 to 5 cubic centimeters of dis-
tilled water and 1 drop of concentrated HC1 (sp. gr. 1.18) was added to insure
acidity. The acidified suspended residue was then extracted with about 10
cubic centimeters of petroleum ether by heating on the hot plate until about 5
cubic centimeters of the solvent remained. After the layers had separated the
supernatant fluid was transferred with a small rubber bulbed pipette to a tared
weighing bottle. The extraction was repeated 5 times. The petroleum ether
solution was then evaporated to dryness in air at room temperature. The weigh-
ing flask was placed in the balance room and allowed to come to constant weight.
The flask was weighed and the tare substracted to obtain the number of milli-
grams of fat contained in 3 cubic centimeters of serum.
By this method the normal range of total lipids is 650—750
milligrams per 100 cubic centimeters of serum. Most of the
determinations were run in duplicate.
REPORT OF CASES
Case 1. B. H., a white girl aged 10 years was first seen on November 3, 1938,
with moderately severe psoriasis vulgaris involving the scalp, back, sacral region,
and extremities which had been present for two years. She had had no previous
treatment. The total blood serum lipids was 770 mgs. per 100 cc. Treatment
was immediately begun with 8 capsules of lipocaic daily. By December 7th
there was very little improvement in the psoriasis and the lipocaic was increased
to 10 capsules daily. The total blood serum lipids on this date was 830 mgs.
per 100 cc. Two weeks later, as there was still no change in the eruption, the
lipocaic was increased to 12 capsules daily. The total blood serum lipids at
this time was 833 mgs. per 100 cc. From this date on there was a steady improve-
ment in the eruption, accompanied also by a decrease in the serum lipids, which
reached a level of 650 mgs. per 100 cc. Lipocaic was then gradually decreased
until it was discontinued entirely on May 15, 1939. At this time there were
only a few slightly sealing lesions remaining. The value for total blood serum
lipids was 785 mgs. per 100 cc.
Case 2. R. L., a white boy aged 12 years, presented himself on November 5,
1938, with moderately severe psoriasis vulgaris of seven months' duration in-
volving the scalp, lower back and extremities. There was moderate pruritus.
He had been treated with various ointments and injections without benefit.
The blood serum at this time showed the total lipids to be 860 mgs. per 100 cc.
The patient was started immediately on 10 capsules of lipocaic daily. Improve-
ment was steady and by January 1, 1939, there were only a few lesions remaining
on the lower extremities. Within two weeks after beginning lipocaic the total
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blood serum lipids had fallen to 600 mgs. per 100 cc. and later reached the low level
of 500 mgs. per cent. In February the number of capsules administered was
decreased and on March 26, 1939, they were discontinued altogether. Final
observation on April 28, 1939, revealed one small, slightly scaly lesion on each
knee. The total blood serum lipids at this examination was 500 mgs. per 100 cc.,
although the patient had received no lipocaic for one month.
Case 3. B. H., a white girl aged 10 years. This patient was first seen on
December 12, 1938, with severe generalized psoriasis vulgaris (fig. 1) which had
been present since the age of five years. Numerous and varied treatments had
been administered from time to time with occasional temporary improvement.
The eruption had never entirely disappeared. The initial total blood-scrnm
Fzo. 1. CAsE 3. PHOTOGRAPH OF LEszoNs ON KNEEs BEFORE STARTING
TREATMENT WITH LIP0cAIC
lipids figure was 600 mgs. per 100 cc. Ten capsules of lipocaic were given daily,
beginning December 13, 1938. Two sveeks later there was central clearing (fig.
2) of the lesions and the total lipid value was 533 mgs. per cent. From this time
on there was steady improvement so that by March 11, 1939, there were only a
few lesions with practically no scales (fig. 3). The lipocaic was then reduced
and on May 19, 1939, discontinued entirely. Final observation on this date
revealed the skin to be completely normal except for two small, slightly scaly
lesions below the left elbow. The total blood serum lipids was 485 mgs. per 100
cc. serum. One month after discontinuing lipocaic, a few recurrent lesions
appeared (fig. 4).
Case 4. J. W., a white man aged 21 years, first presented himself on Jannary
11, 1939, with generalized psoriasis of the guttate type which had been present
for three and one-half years. There was moderate pruritus. Previous treatment
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had consisted of crude coal tar ointment. About three years previous to this
time the patient had had a complete remission lasting for six months. Total
blood serum lipids at this time was 700 mgs. per 100 cc. Treatment was started
FIG. 2. CASE 3. PHOTOGRAPH OF LESIONS ON KNEES 14 DAYS AFTER BEGINNING
LIP0cAIc
FIG. 3. CASE 3. PHOTOGRAPH OF LESIONS ON KNEEs 90 DAYS AFTER
BEGINNING LIP0cAIc
with 12 capsules of lipocaic daily. Within one week there was slight improve-
ment and the pruritus had decreased. The total blood serum lipids was 560
mgs. per 100 cc. Following this observation there was no further improvement in
the eruption, even though the lipocaic was increased to 14 capsules daily on Feb-
ruary 14, 1939. The patient was seen last on March 15, 1939, after which he failed
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to return. His psoriasis had remained stationary since the first week of
treatment.
Cesc 5. C. C., a white woman aged 34 years, was first seen on February 14,
1939, with generalized psoriasis vulgaris which had been present since the age of
Fzu. 4. CASE 3. PHOTOGRAPH OF KNEES ONE MONTH AFTER DISCONTINUING
LIP0CAIc, SHOWING RECURRENCE OF A SMALL LESION ON RIGHT KNEE,
WHICH WAS NOT PRESENT AT THE TIME LIP0CAIC WAs STOPPED
15 years. No treatment had been given for the past few years. The total blood
serum lipids at this visit was 710 mgs. per 100 cc. Treatment was begun with
12 capsules of lipocaic daily. This patient obtained marked and steady improve-
ment under therapy, and on April 13, 1939 practically all that remained of the
eruption was residual pigmentation. The patient volunteered the information
that she was less nervous since taking the lipocaic, and the lesions were less
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pruritic. The total blood serum lipids at this time was 565 mgs. per 100 cc.
Lipocaic was then gradually reduced until on May 19, 1939, it was discontinued
entirely. The skin at this time was entirely clear except for some remaining
pigmentation. The total blood serum lipids was 465 mgs. per cent. It is interest-
ing to note that for about one week during March, 1939, the patient received no
lipocaic and stated that she became more nervoas, the lesions became prominent,
and were more pruritic.
Case 6. E. F., a white man aged 32 years, was first seen May 8, 1939, at which
time he presented lesions on the scalp, palms, soles and genitalia of one year's
duration. There were also mild symptoms of psoriasis arthropathica. No treat-
ment had been received. Total blood serum lipids at this time was 965 mgs. per
100 cc. Treatment was started with 12 capsules of lipocaic daily. Two weeks
later there was slight improvement of the hands. The total blood serum lipids
at this time was 1000 mgs. per cent. The patient was next observed approxi-
mately one month after the beginning of treatment. At this visit no further im-
provement was noted and the patient complained of mild joint pains. The total
blood serum lipids was 750 mgs. per 100 cc. This patient is still under treatment.
The accompanying table illustrates the clinical course of the
eruption, along with changes in blood lipids (table I).
COMMENT
In our experience the normal total serum lipid value ranged
from 650—750 mgs. per 100 cc. by the method used. In the six
patients whom we studied, three had an initial lipemia, two were
within normal limits and one had a subnormal reading. No
correlation between the initial total lipid figure and the response
to lipocaic therapy could be formulated. Regardless of whether
their total lipids were elevated, all patients experienced slight
improvement after one or two weeks of treatment. However,
subsequent improvement appeared to depend upon maintaining
the serum lipids at the lower limits of normal or below. This is
well illustrated by the fact that no patient showed significant
improvement until the total serum lipids had reached a level of
650 mgs. per 100 cc. or less. In the one case in which there was
an initial subnormal value it will be noted that at the time of
greatest improvement the serum lipids were decreased below the
initial figure. Case 1 illustrates this point very definitely.
Marked improvement here was not noted until after three months
of therapy, when, under increased dosage of lipocaic the serum
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lipids fell to 650 mgs. per 100 cc. Prior to this time, the lowest
level had been 730 mgs. per 100 cc. of serum.
The one case in which failure to respond was seen (case 4) is
somewhat difficult to explain. The total serum lipids was 650
mgs. per 100 cc. or less during the entire course, except for one
occasion. However, the patient was lost from observation after
only two months of treatment, which in our opinion is too short a
period to judge the effect of lipocaic therapy. It is interesting
to note that this was our one case of guttate psoriasis. Madden
(6) stated that the guttate lesions cleared faster than the invet-
erate plaques when treated with a low fat diet.
Healing in most lesions began centrally. In case 5 after clear-
ing of the lesions there was definite residual pigmentation. One
noteworthy fact was the stubbornness with which the last few
remaining lesions persisted. These usually proved resistant to
further lipocaic therapy. Pruritus when present was usually
promptly relieved by treatment.
We realize of course that it is difficult if not impossible to
evaluate any therapeutic procedure from such a small series of
cases, and particularly in a disease characterized by spontaneous
remissions. However, it should be borne in mind that these
patients cleared during the winter months, a season when psori-
asis is generally most severe. It must also be remembered that
these patients were not hospitalized or restricted in any manner,
dietary or otherwise, and that no local therapy of any kind was
applied.
What the future course will be for these patients cannot be
foretold as yet. Two patients who were completely relieved,
and who have not received lipocaic for several months have
noticed lesions beginning to reappear. The tendency to relapse
is of course well known. There is a possibility, however, that
once a psoriatic is free of lesions he can be kept free by a small
daily maintenance dose of lipocaic. This remains to be deter-
mined.
In view of our results we feel justified in agreeing with those
authors who maintain that in psoriasis there is present a dis-
turbance of the lipid metabolism.
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In closing it must be stressed that we do not offer lipocaic as a
cure for psoriasis, but on the basis of our study thus far it prom-
ises to be a valuable adjunct in the treatment of this disease.
As this work continues we shall report a larger series of patients,
together with the ultimate outcome of those who have been
relieved.
SUMMARY
1. Six patients with psoriasis are presented who were treated
with lipocaic. Four showed marked improvement, one failed to
respond to lipocaic therapy and the other one has shown slight
improvement after four weeks of treatment.
2. Before treatment was started, three patients had lipemia,
two had blood lipid values within normal limits, and one showed
subnormal lipid value.
3. Lipocaic is shown to lower the blood serum lipids to normal
or below normal level in patients with psoriasis.
4. This study lends support to the idea that psoriasis is asso-
ciated with a deranged fat metabolism.
5. Lipocaic promises to be a valuable adjunct in the treatment
of psoriasis.
Medical-Professional Bldg.,
Corpus Christi, Texas.
905 East 59th &., Chicago.
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